

Introduction

S1 **Neurofibromatosis Clinical Trials—REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead**

A.M. Gross, S.R. Plotkin, and B.C. Widemann, on behalf of the REiNS International Collaboration

Patient Engagement

S4 **Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement**

V.L. Merker, A.J. Lessing, I. Moss, M. Hussey, B. Oberlander, T. Rose, R. Thalheimer, T. Wirtanen, P.L. Wolters, A.M. Gross, and S.R. Plotkin, on behalf of the REiNS International Collaboration

Cutaneous Neurofibromas

S15 **Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials**

A. Cannon, D.C. Pichard, P.L. Wolters, S. Adsit, G. Erickson, A.J. Lessing, P. Li, W. Narmore, C. Röhl, T. Rosser, B.C. Widemann, J.O. Blakeley, and S.R. Plotkin, on behalf of the REiNS International Collaboration

S25 **Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1**

S. Maguiness, Y. Berman, N. Rubin, M. Dodds, S.R. Plotkin, C. Wong, and C. Moertel, on behalf of the REiNS International Collaboration

S32 **Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials**

R.D. Thalheimer, V.L. Merker, K.I. Ly, A. Champlain, J. Sawaya, N.L. Askenazi, H.P. Herr, J.L.W. Da, J.T. Jordan, A. Muzikansky, E.M. Pearce, F.H. Sakamoto, J.O. Blakeley, R.R. Anderson, and S.R. Plotkin, on behalf of the REiNS International Collaboration

S42 **Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research**

D. Wallis, A. Stemmer-Rachamimov, S. Adsit, B. Korf, D. Pichard, J. Blakeley, and K.Y. Sarin, on behalf of the REiNS International Collaboration

Patient Reported Outcomes

S50 **Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials**

P.L. Wolters, A.-M. Vranceanu, H.L. Thompson, S. Martin, V.L. Merker, A. Baldwin, C. Barnett, K.S. Koetsier, C.M. Hingtgen, C.J. Funes, J.H. Tonsgard, E.K. Schorry, T. Allen, T. Smith, B. Franklin, and S. Reeve, on behalf of the REiNS International Collaboration

S64 **Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials**

H.L. Thompson, A. Blanton, B. Franklin, V.L. Merker, K.H. Franck, and D.B. Welling, on behalf of the REiNS International Collaboration

S73 **Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1**

J.A. Janusz, B.P. Klein-Tasman, J.M. Payne, P.L. Wolters, H.L. Thompson, S. Martin, P. de Blank, N. Ullrich, A. del Castillo, M. Hussey, K.K. Hardy, K. Haebich, T. Rosser, M.A. Toledo-Tamula, and K.S. Walsh, on behalf of the REiNS International Collaboration

S81 **Recommendations for Measurement of Attention Outcomes in Preschoolers With Neurofibromatosis**

B.P. Klein-Tasman, K. Lee, H.L. Thompson, J. Janusz, J.M. Payne, S. Pardej, P. de Blank, T. Kennedy, K.M. Janke, A. Castillo, and K.S. Walsh, on behalf of the REiNS International Collaboration

Biomarkers

S91 **REiNS: Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use**

C. Bettegowda, M. Upadhayaya, D.G. Evans, A.R. Kim, D. Mathios, and C.O. Hanemann, on behalf of the REiNS International Collaboration

Functional Outcomes

S99 **Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2**

S. Akshintala, N. Khalil, K. Yohay, A. Muzikansky, J. Allen, A. Yaffe, A.M. Gross, M.J. Fisher, J.O. Blakeley, B. Oberlander, M. Pudiel, C. Engelson, J. Obletz, C. Mitchell, B.C. Widemann, D.A. Stevenson, and S.R. Plotkin

Imaging

S111 **Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment**

S. Ahlawat, K.I. Ly, L.M. Fayad, M.J. Fisher, A.J. Lessing, D.J. Berg, J.M. Salamon, V.-F. Mautner, D. Babovic-Vuksanovic, E. Dombi, G. Harris, S.R. Plotkin, and J. Blakeley, on behalf of the REiNS International Collaboration

Publication of this supplement was supported by the Children's Tumor Foundation. The authors gratefully acknowledge the participation of the entire REiNS community, the Food and Drug Administration (Martha Donoghue, Denise Casey), and the Cancer Therapy Evaluation Program (William Timmer) at the National Cancer Institute.

Neurology[®]

97 (7 Supplement 1)
Neurology 2021;97;S91-S80

This information is current as of January 1, 2021

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/97/7_Supplement_1.citation.full
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

